NAN-CS101: A first-in-human Phase 1 open-label dose-escalation study of AB-1002 gene therapy for the treatment of NYHA class III heart failure
17 May 2025 (08:00 - 12:45)
Organised by: 
About the speaker
Mass General Brigham, Boston (United States of America)
5 More presentations in this session
Doctor J. Torres Zamudio (Cordoba, ES)
Professor T. Kempf (Hannover, DE)
Doctor M. Fudim (Durham, US)
Professor S. Anker (Berlin, DE)
Access the full session
The Event
Heart Failure 2025
17 May - 20 May 2025
